BamSEC and AlphaSense Join Forces
Learn More

Prime Medicine Inc.

NASDAQ: PRME    
Share price (12/24/24): $2.76    
Market cap (12/24/24): $362 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 8 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”
12/34/56
EX-10.2
from 10-Q 86 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Research Collaboration and License Agreement Dated as of September 28, 2024 by and Between Prime Medicine, Inc. and Juno Therapeutics, Inc
12/34/56
EX-10.1
from 10-Q 45 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Prime Medicine, Inc. Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Prime Medicine, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.22
from 10-K 3 pages Twelfth Amendment to License Agreement
12/34/56
EX-10.1
from 8-K 12 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 2 pages Amendment No. 1 to Employment Agreement
12/34/56
EX-10.5
from 10-Q 2 pages Eleventh Amendment to License Agreement
12/34/56
EX-10.4
from 10-Q 3 pages Tenth Amendment to License Agreement
12/34/56
EX-10.3
from 10-Q 2 pages Nineth Amendment to License Agreement
12/34/56
EX-10.2
from 10-Q 3 pages Sixth Amendment to License Agreement
12/34/56
EX-10.1
from 10-Q 33 pages Material contract
12/34/56
EX-10.18
from 10-K 92 pages Material contract
12/34/56
EX-10.17
from 10-K 4 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Third Amendment to License Agreement
12/34/56
EX-10.23
from S-1/A 14 pages Employment Agreement
12/34/56
EX-10.3
from S-1/A 17 pages Prime Medicine, Inc. 2022 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 53 pages Prime Medicine, Inc. 2022 Stock Option and Incentive Plan
12/34/56
EX-10.1
from S-1/A 90 pages Prime Medicine, Inc. Amendment No. 3 to the 2019 Stock Option and Grant Plan
12/34/56
EX-10.22
from S-1 7 pages Employee Confidentiality, Assignment and Nonsolicitation Agreement
12/34/56
EX-10.21
from S-1 3 pages December 20, 2019 Andrew V. Anzalone, MD, Phd
12/34/56